Galderma set to launch Nuvo's Pliaglis in EU
This article was originally published in Scrip
Dermatology company Galderma has received its first three EU marketing licences for its topical pain drug Pliaglis (tetracaine and lidocaine), with plans to launch in the first half of 2013.
You may also be interested in...
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.